SCHEDULE: Kingdon Capital Management Discloses 5.1% Passive Stake in Jasper Therapeutics

Kingdon Capital Management, L.L.C. and Mark Kingdon have disclosed a passive beneficial ownership of 5.1% in Jasper Therapeutics, Inc.'s Voting Common Stock.

Summary

• Kingdon Capital Management, L.L.C. and Mark Kingdon have filed a Schedule 13G, reporting beneficial ownership of 765,000 shares of Jasper Therapeutics, Inc.'s Voting Common Stock.
• This ownership represents 5.1% of the outstanding class of securities.
• The shares are held for investment purposes and not with the intent to change or influence the control of Jasper Therapeutics, Inc.
• Both Kingdon Capital Management, L.L.C. and Mark Kingdon share voting and dispositive power over all 765,000 shares.
• The event triggering this filing, crossing the 5% ownership threshold, occurred on July 3, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by Kingdon Capital Management and Mark Kingdon in Jasper Therapeutics, Inc., which can be interpreted as a positive signal of investor confidence in the company's long-term prospects, despite being a passive stake.

Positives

• The disclosure of a 5.1% stake by Kingdon Capital Management, L.L.C. and Mark Kingdon signifies a notable investment by a recognized financial entity in Jasper Therapeutics, Inc.
• The stated passive nature of the investment suggests confidence in the company's current management and strategic direction without an intent to seek control.

Negatives

• No specific negative information about Jasper Therapeutics, Inc. is contained within this ownership disclosure filing.

Risks

• The filing itself does not detail specific risks related to Jasper Therapeutics, Inc.'s operations or financial health, as it is solely a disclosure of ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor like Kingdon Capital Management may instill confidence among existing shareholders and potentially attract new investors.

Next Steps

• Kingdon Capital Management, L.L.C. and Mark Kingdon will continue to comply with SEC reporting requirements for their beneficial ownership in Jasper Therapeutics, Inc.

Key Dates

Keywords

Jasper Therapeutics, Kingdon Capital Management, Mark Kingdon, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Passive Stake